Edgewise Therapeutics (EWTX) 2025 Conference May 20, 2025 09:00 AM ET Speaker0 Thanks everyone for being here. Our next presenting company is Edgewise Therapeutics represented by Kevin, their c CEO, and Broad, their chief operating officer. So thanks for being here. Speaker1 Thank you, Kymena. Great. Yeah. Speaker0 So maybe we'll just jump right in. I mean, recently, you guys reported four week data for EDG seven thousand five hundred in HCM, and it's got a fairly unique efficacy profile. So maybe can you c ...

Core Viewpoint - Edgewise Therapeutics, Inc. (EWTX) has received a Zacks Rank 2 (Buy) upgrade due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][4]. Earnings Estimates and Ratings - The Zacks rating system is primarily based on a company's changing earnings picture, specifically tracking the Zacks Consensus Estimate for EPS from sell-side analysts [2]. - The Zacks rating upgrade for Edgewise Therapeutics reflects a positive outlook on its earnings, which could positively affect its stock price [4][6]. Impact of Earnings Estimates on Stock Prices - Changes in a company's future earnings potential, as indicated by earnings estimate revisions, are strongly correlated with near-term stock price movements [5]. - Institutional investors utilize earnings estimates to determine the fair value of a company's shares, influencing their buying or selling actions, which subsequently affects stock prices [5]. Recent Performance of Edgewise Therapeutics - Edgewise Therapeutics is projected to earn -$1.82 per share for the fiscal year ending December 2025, indicating a year-over-year decline of 25.5% [9]. - Over the past three months, the Zacks Consensus Estimate for Edgewise Therapeutics has increased by 2.1%, suggesting a positive trend in earnings estimates [9]. Zacks Rank System Overview - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 (Strong Buy) stocks historically generating an average annual return of +25% since 1988 [8]. - The upgrade of Edgewise Therapeutics to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [11].

Shares of Edgewise Therapeutics, Inc. (EWTX) have gained 14.4% over the past four weeks to close the last trading session at $14.89, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $40.90 indicates a potential upside of 174.7%.The average comprises 10 short-term price targets ranging from a low of $14 to a high of $52, with a standard deviation of $14.28. While the lowest estima ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40236 Edgewise Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other juri ...

News Release Edgewise Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights – Announced positive top-line results from Phase 2 CIRRUS-HCM trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) – – Strengthened balance sheet with net proceeds of approximately $188 million from the April 2025 public of ering; pro-forma cash balance exceeds $624 million – Exhibit 99.1 – On track to report data from the Phase 2 LYNX and FOX trials of sevasemten in Duchenne muscular dystrophy ( ...

Shares of Edgewise Therapeutics (EWTX) plunged 47.7% in a week, likely due to safety concerns for its investigational candidate, EDG-7500, in patients with obstructive or nonobstructive hypertrophic cardiomyopathy (HCM), despite positive mid-stage study results.EWTX is evaluating EDG-7500, a novel oral, selective, cardiac sarcomere modulator with a unique mechanism of action, in the ongoing phase II CIRRUS-HCM study. The latest data readout is from Part B and Part C of the CIRRUS-HCM study, which included 1 ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

BOULDER, Colo., April 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a leading muscle disease biopharmaceutical company, today announced the pricing of an underwritten offering of 9,935,419 shares of its common stock at an offering price of $20.13 per share. Edgewise anticipates gross proceeds from the offering to be approximately $200 million, before deducting underwriting discounts and commissions and offering expenses. The closing of the offering is expected to occur on April 3, 2025 ...

– Phase 2 trial of EDG-7500 demonstrated rapid and clinically meaningful reductions in LVOT gradients in participants with obstructive HCM –– Four-week treatment with EDG-7500 demonstrated substantial improvements in measures of feel and function, reductions in key cardiac biomarkers and positive trends in measures of diastolic function –– EDG-7500 was generally well-tolerated; clinical activity was observed without meaningful changes in LVEF, including no participant with a value below 50% –BOULDER, Colo., ...

Group 1 - Edgewise Therapeutics will hold a live webcast on April 2, 2025, to discuss top-line data of EDG-7500 from the Phase 2 CIRRUS-HCM trial [1] - The webcast will feature two leading investigators in the field of hypertrophic cardiomyopathy (HCM) [1] - An accompanying slide presentation will be available for participants [1] Group 2 - EDG-7500 is a novel oral, selective cardiac sarcomere modulator aimed at addressing impaired cardiac relaxation in HCM and other diastolic dysfunction diseases [2] - The drug is currently in Phase 2 clinical development [2][3] - Edgewise Therapeutics is focused on developing therapeutics for muscular dystrophies and serious cardiac conditions, with a commitment to improving patient lives [3]